Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study

References

• Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):1–13. doi:10.1056/NEJMoa2001017.
   PubMed Web of Science ®Google Scholar
• The Lancet O. COVID-19: global consequences for oncology. Lancet Oncol. 2020;21:467. doi:10.1016/S1470-2045(20)30175-3.
   PubMed Web of Science ®Google Scholar
• Desai A, Gupta R, Advani S, Ouellette L, Kuderer NM, Lyman GH, Li A. Mortality in hospitalized patients with cancer and coronavirus disease 2019: a systematic review and meta‐analysis of cohort studies. Cancer. 2021;127(9):1459–68. doi:10.1002/cncr.33386.
   PubMed Web of Science ®Google Scholar
• Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–37. doi:10.1016/S1470-2045(20)30096-6.
   PubMed Web of Science ®Google Scholar
• Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–91. doi:10.1158/2159-8290.CD-20-0422.
   PubMed Web of Science ®Google Scholar
• Wang Q, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 Infection. JAMA Oncol. 2020;7(2):220. doi:10.1001/jamaoncol.2020.6178.
   Web of Science ®Google Scholar
• Garg S, Patel K, Pham H, Whitaker M, O’Halloran A, Milucky J, Anglin O, Kirley PD, Reingold A, Kawasaki B, et al. Clinical trends among U.S. adults hospitalized with COVID-19, March to December 2020 : a cross-sectional study. Ann Intern Med. 2021;174(10):1409–19. doi:10.7326/M21-1991.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Safety and efficacy of the ChAdox1 nCov-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi:10.1016/S0140-6736(20)32661-1.
   PubMed Web of Science ®Google Scholar
• Ribas A, Sengupta R, Locke T, Zaidi SK, Campbell KM, Carethers JM, Jaffee EM, Wherry EJ, Soria J-C, D’Souza G. Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. Cancer Discov. 2021;11(2):233–36. doi:10.1158/2159-8290.CD-20-1817.
   PubMed Web of Science ®Google Scholar
• Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A, Yust-Katz S, Zer A, Benouaich-Amiel A, Ben-Zvi H, Moskovits N, Brenner B, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(8):1133. doi:10.1001/jamaoncol.2021.2155.
   PubMed Web of Science ®Google Scholar
• Di Noia V, Pimpinelli F, Renna D, Barberi V, Maccallini MT, Gariazzo L, Pontone M, Monti A, Campo F, Taraborelli E, et al. Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution. Clin Cancer Res. 2021;27(24):6815–23. doi:10.1158/1078-0432.CCR-21-2439.
   PubMed Web of Science ®Google Scholar
• Gounant V, Ferré VM, Soussi G, Charpentier C, Flament H, Fidouh N, Collin G, Namour C, Assoun S, Bizot A, et al. Efficacy of severe acute respiratory syndrome coronavirus-2 vaccine in patients with thoracic cancer: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses. J Thorac Oncol. 2022;17(2):239–51. doi:10.1016/j.jtho.2021.10.015.
   PubMed Web of Science ®Google Scholar
• Abbott ARCHITECT SARS-CoV-2 IgG II quant reagent -instructions for use- US food and drug administration. [accessed 2022 Sep 23]. https://www.fda.gov/media/146371/download.
   Google Scholar
• Elecsys anti-CoV-2 S -instructions for use- US food and drug administration. [accessed 2022 May 1]. https://www.fda.gov/media/137605/download.
   Google Scholar
• Oculo-respiratory syndrome following influenza vaccination: review of post-marketing surveillance through four influenza seasons in Canada. Can Commun Dis Rep. 2005;31(21):217–25.
   PubMedGoogle Scholar
• National Advisory Committee on I. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Supplementary statement on influenza vaccination: continued use of fluviral influenza vaccine in the 2000-2001 season. Can Commun Dis Rep. 2001;27:1–3.
   Google Scholar
• Products. ECfPM. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). London: European Agency for the Evaluation of Medical Products; 1997. [accessed 2015 Feb 23]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf.
   Google Scholar
• Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, Dold C, Fuskova M, Gilbert SC, Hirsch I, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032–40. doi:10.1038/s41591-021-01540-1.
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Sci (New York, NY). 2022;375(6576):43–50. doi:10.1126/science.abm3425.
   Google Scholar
• First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human). [accessed 2022 Sep 21]. https://www.nibsc.org/documents/ifu/20-136.pdf.
   Google Scholar
• Knezevic I, Mattiuzzo G, Page M, Minor P, Griffiths E, Nuebling M, Moorthy V. WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe. 2022;3(3):e235–40. doi:10.1016/S2666-5247(21)00266-4.
   PubMedGoogle Scholar
• Lukaszuk K, Kiewisz J, Rozanska K, Dabrowska M, Podolak A, Jakiel G, Woclawek-Potocka I, Lukaszuk A, Rabalski L. Usefulness of IVD kits for the assessment of SARS-CoV-2 antibodies to evaluate the humoral response to vaccination. Vaccines. 2021;9(8):840. doi:10.3390/vaccines9080840.
   Web of Science ®Google Scholar
• Becerril-Gaitan A, Vaca-Cartagena BF, Ferrigno AS, Mesa-Chavez F, Barrientos-Gutiérrez T, Tagliamento M, Lambertini M, Villarreal-Garza C. Immunogenicity and risk of SARS-CoV-2 infection after COVID-19 vaccination in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2022;163:243–260.
   PubMed Web of Science ®Google Scholar
• Barrière J, Chamorey E, Adjtoutah Z, Castelnau O, Mahamat A, Marco S, Petit E, Leysalle A, Raimondi V, Carles M. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors. Ann Oncol. 2021;32(8):1053–55. doi:10.1016/j.annonc.2021.04.019.
   PubMed Web of Science ®Google Scholar
• Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39(8):1081–90.e2. doi:10.1016/j.ccell.2021.06.002.
   PubMed Web of Science ®Google Scholar
• Takakuwa T, Nakagama Y, Yasugi M, Maeda T, Matsuo K, Kiritoshi A, Deguchi R, Hagawa N, Shibata W, Oshima K, et al. Discrepant antigen-specific antibody responses causing SARS-CoV-2 persistence in a patient receiving B-cell-targeted therapy with rituximab. Int Med. 2021;60(23):3827–31. doi:10.2169/internalmedicine.7884-21.
   PubMed Web of Science ®Google Scholar
• Tran S, Truong TH, Narendran A. Evaluation of COVID-19 vaccine response in patients with cancer: an interim analysis. Eur J Cancer. 2021;159:259–74. doi:10.1016/j.ejca.2021.10.013.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadska D, Snipe HD, Brown JS, Workman L, Zar HJ, et al. Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine. 2022;40(2):306–15. doi:10.1016/j.vaccine.2021.12.006.
   PubMed Web of Science ®Google Scholar
• Corti C, Antonarelli G, Scotté F, Spano JP, Barrière J, Michot JM, André F, Curigliano G. Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review. Ann Oncol. 2021;33(2):158–68. doi:10.1016/j.annonc.2021.10.014.
   PubMed Web of Science ®Google Scholar
• Palich R, Veyri M, Marot S, Vozy A, Gligorov J, Maingon P, Marcelin A-G, Spano J-P. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients. Ann Oncol. 2021;32(8):1051–53. doi:10.1016/j.annonc.2021.04.020.
   PubMed Web of Science ®Google Scholar
• Webber TB, Provinciali N, Musso M, Ugolini M, Boitano M, Clavarezza M, D’Amico M, Defferrari C, Gozza A, Briata IM, et al. Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment. Eur J Cancer. 2021;159:105–12. doi:10.1016/j.ejca.2021.09.030.
   PubMed Web of Science ®Google Scholar
• Wumkes ML, van der Velden AM, Los M, Leys MB, Beeker A, Nijziel MR, van der Velden AWG, Westerman M, Meerveld-Eggink A, Rimmelzwaan GF, et al. Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours. Vaccine. 2013;31(52):6177–84. doi:10.1016/j.vaccine.2013.10.053.
   PubMed Web of Science ®Google Scholar
• Ma Y, Liu N, Wang Y, Zeng J, Hu Y-Y, Hao W, Shi H, Zhu P, Lv J, Fan W, et al. Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis. J ImmunoTher Cancer. 2021;9(11):e003712. doi:10.1136/jitc-2021-003712.
   PubMed Web of Science ®Google Scholar
• Nakagama Y, Nitahara Y, Kaku N, Tshibangu-Kabamba E, Kido Y. A dual-antigen SARS-CoV-2 serological assay reflects antibody avidity. J Clin Microbiol. 2022;60(2):e0226221. doi:10.1128/jcm.02262-21.
   PubMed Web of Science ®Google Scholar
• Pichler D, Baumgartner M, Kimpel J, Rössler A, Riepler L, Bates K, Fleischer V, von Laer D, Borena W, Würzner R. Marked increase in avidity of SARS-CoV-2 antibodies 7–8 months after infection is not diminished in old age. J Infect Dis. 2021;224(5):764–70. doi:10.1093/infdis/jiab300.
   PubMed Web of Science ®Google Scholar
• Nitahara Y, Nakagama Y, Kaku N, Candray K, Michimuko Y, Tshibangu-Kabamba E, Kaneko A, Yamamoto H, Mizobata Y, Kakeya H, et al. High-resolution linear epitope mapping of the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 mRNA vaccine recipients. Microbiol Spectr. 2021;9(3):e0096521. doi:10.1128/Spectrum.00965-21.
   PubMed Web of Science ®Google Scholar
• Matsuura T, Fukushima W, Nakagama Y, Kido Y, Kase T, Kondo K, Kaku N, Matsumoto K, Suita A, Komiya E, et al. Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: a prospective cohort study in Japan. Vaccine. 2022;40(38):5631–40. doi:10.1016/j.vaccine.2022.08.018.
   PubMed Web of Science ®Google Scholar
• Perez-Saez J, Zaballa M-E, Yerly S, Andrey DO, Meyer B, Eckerle I, Balavoine J-F, Chappuis F, Pittet D, Trono D, et al. Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. Clin Microbiol Infect. 2021;27(11):1695.e7–.e1. doi:10.1016/j.cmi.2021.06.040.
   PubMed Web of Science ®Google Scholar
• Bauer G. The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2. Int J Infect Dis. 2021;106:61–64. doi:10.1016/j.ijid.2021.01.061.
   PubMed Web of Science ®Google Scholar
• Shulman RM, Weinberg DS, Ross EA, Ruth K, Rall GF, Olszanski AJ, Helstrom J, Hall MJ, Judd J, Chen DYT, et al. Adverse events reported by patients with cancer after administration of a 2-dose mRNA COVID-19 vaccine. J Natl Compr Canc Net. 2022;20(2):160–66. doi:10.6004/jnccn.2021.7113.
   PubMed Web of Science ®Google Scholar
• Marra AR, Kobayashi T, Suzuki H, Alsuhaibani M, Tofaneto BM, Bariani LM, Auler MDA, Salinas JL, Edmond MB, Doll M, et al. Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: a systematic literature review and meta-analysis. J Infect. 2022;84(3):297–310. doi:10.1016/j.jinf.2021.12.035.
   PubMed Web of Science ®Google Scholar
• Chodick G, Tene L, Rotem RS, Patalon T, Gazit S, Ben-Tov A, Weil C, Goldshtein I, Twig G, Cohen D, et al. The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data. Clin Infect Dis. 2022;74(3):472–78. doi:10.1093/cid/ciab438.
   PubMed Web of Science ®Google Scholar